Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1274532

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1274532

Biologic & Biosimilar RA Drugs Global Market Report 2023

Published: Pre-Order
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

“Biologic & Biosimilar RA Drugs Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biologic & biosimilar ra drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biologic & biosimilar ra drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The biologic & biosimilar ra drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Source: Microbial; Mammalian; Other Sources
  • 2) By Disease: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Other Diseases
  • 3) By Manufacturing: Outsourced; In-House
  • 4) By Mode Of Purchase: Prescription Drugs; Over-The-Counter (OTC) Drugs
  • 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Samsung BioLogics Co. Ltd.; Amgen Inc.; Novo Nordisk A/S; AbbVie Inc.; Sanofi Pasteur
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the biologic & biosimilar ra drugs market are Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Sanofi Pasteur, Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., and Gedeon Richter Plc.

The global biologic & biosimilar RA drugs market is expected to grow from $12.08 billion in 2022 to $12.65 billion in 2023 at a compound annual growth rate (CAGR) of 4.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biologic & biosimilar RA drugs market is expected to grow to $15.19 billion in 2027 at a CAGR of 4.7%.

The biologics and biosimilars RA drugs market consists of sales of branded and generic biologics and biosimilar RA drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Biologics and biosimilars refer to a class of drugs that are extracted from living organisms such as living cells, microorganisms, and other living creatures. Biosimilars are biologics that have similar characteristics to an already approved biological molecule. These drugs are used for the treatment of rheumatoid arthritis.

North America was the largest region in the biologic & biosimilar RA drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologic & biosimilar RA drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main sources of biologic & biosimilar RA drugs are microbial, mammalian and others. Microbial sources refer to sources such as bacteria, yeast, and fungi. The various disease involved are oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others whose drugs are manufactured by outsourced and in-house. They are sold by prescription drugs, over-the-counter (OTC) drugs in hospital pharmacies, retail pharmacies, and online pharmacies.

The rising older population and increasing incidence of rheumatoid arthritis are driving the biologics and biosimilars RA drugs market forward. The older population refers to people who are aged 60 years or older. Rheumatoid arthritis is an autoimmune disease in which the immune system of a person attacks its healthy cells and the joints of the person are affected. Rheumatoid arthritis is most likely to affect people in old age as the immune system gets weaker with old age. Biologics and biosimilar RA drugs are very useful for the treatment of rheumatoid arthritis as compared to conventional drugs. For instance, according to the world health organization (WHO), a Switzerland-based specialized health agency of the United Nations, there were about 1 billion people aged 60 and above in the world in 2020 and this population is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, according to the Centers for Disease Control and Prevention, a US-based governmental public health agency, the number of adults suffering from arthritis in the USA is expected to increase to 78.4 million by 2040 while 34.6 million people may suffer from arthritis-related activity limitations. Therefore, the increasing geriatric population along with the increasing RA cases is driving the biologics and biosimilars RA drugs market forward.

Product innovations are a key trend gaining popularity in the biologics and biosimilars RA drugs market. Major companies in the biologics and biosimilars RA drugs market are introducing innovative products to sustain their position in the market. For instance, in January 2020, Bio-Thera Solutions, a China-based biosimilar developer and manufacturer, launched QLETLI. The new product is the first adalimumab biosimilar approved by the China National Medical Products Administration (NMPA). It will be useful for the treatment of rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis.

In November 2022, Biocon, an India-based biopharmaceutical company acquired Viatris' global biosimilars business for $3 billion. The acquisition brings patients, consumers, and payors closer to Biocon Biologics by giving it direct commercial capabilities and supporting infrastructure in numerous emerging markets as well as advanced markets. Viatris is a US-based pharmaceutical company manufacturing biosimilars for the treatment of rheumatoid arthritis along with other diseases.

The countries covered in the biologic & biosimilar RA drugs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The biologic & biosimilar RA drugs market research report is one of a series of new reports from The Business Research Company that provides biologic & biosimilar RA drugs market statistics, including biologic & biosimilar RA drugs industry global market size, regional shares, competitors with biologic & biosimilar RA drugs market share, detailed biologic & biosimilar RA drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the biologic & biosimilar RA drugs industry. This biologic & biosimilar RA drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Product Code: r6517

Table of Contents

1. Executive Summary

2. Biologic & Biosimilar RA Drugs Market Characteristics

3. Biologic & Biosimilar RA Drugs Market Trends And Strategies

4. Biologic & Biosimilar RA Drugs Market - Macro Economic Scenario

  • 4.1. COVID-19 Impact On Biologic & Biosimilar RA Drugs Market
  • 4.2. Ukraine-Russia War Impact On Biologic & Biosimilar RA Drugs Market
  • 4.3. Impact Of High Inflation On Biologic & Biosimilar RA Drugs Market

5. Biologic & Biosimilar RA Drugs Market Size And Growth

  • 5.1. Global Biologic & Biosimilar RA Drugs Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Biologic & Biosimilar RA Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Biologic & Biosimilar RA Drugs Market Segmentation

  • 6.1. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Microbial
  • Mammalian
  • Other Sources
  • 6.2. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Other Diseases
  • 6.3. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Outsourced
  • In-House
  • 6.4. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Prescription Drugs
  • Over-The-Counter (OTC) Drugs
  • 6.5. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Biologic & Biosimilar RA Drugs Market Regional And Country Analysis

  • 7.1. Global Biologic & Biosimilar RA Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Biologic & Biosimilar RA Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Biologic & Biosimilar RA Drugs Market

  • 8.1. Asia-Pacific Biologic & Biosimilar RA Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.3. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Biologic & Biosimilar RA Drugs Market

  • 9.1. China Biologic & Biosimilar RA Drugs Market Overview
  • 9.2. China Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.3. China Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Biologic & Biosimilar RA Drugs Market

  • 10.1. India Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.2. India Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Biologic & Biosimilar RA Drugs Market

  • 11.1. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.2. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Biologic & Biosimilar RA Drugs Market

  • 12.1. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.2. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Biologic & Biosimilar RA Drugs Market

  • 13.1. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.2. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Biologic & Biosimilar RA Drugs Market

  • 14.1. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.2. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Biologic & Biosimilar RA Drugs Market

  • 15.1. Western Europe Biologic & Biosimilar RA Drugs Market Overview
  • 15.2. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.3. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Biologic & Biosimilar RA Drugs Market

  • 16.1. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.2. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Biologic & Biosimilar RA Drugs Market

  • 17.1. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.2. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Biologic & Biosimilar RA Drugs Market

  • 18.1. France Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.2. France Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Biologic & Biosimilar RA Drugs Market

  • 19.1. Eastern Europe Biologic & Biosimilar RA Drugs Market Overview
  • 19.2. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.3. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Biologic & Biosimilar RA Drugs Market

  • 20.1. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.2. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Biologic & Biosimilar RA Drugs Market

  • 21.1. North America Biologic & Biosimilar RA Drugs Market Overview
  • 21.2. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.3. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Biologic & Biosimilar RA Drugs Market

  • 22.1. USA Biologic & Biosimilar RA Drugs Market Overview
  • 22.2. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.3. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Biologic & Biosimilar RA Drugs Market

  • 23.1. South America Biologic & Biosimilar RA Drugs Market Overview
  • 23.2. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.3. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Biologic & Biosimilar RA Drugs Market

  • 24.1. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.2. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Biologic & Biosimilar RA Drugs Market

  • 25.1. Middle East Biologic & Biosimilar RA Drugs Market Overview
  • 25.2. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.3. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Biologic & Biosimilar RA Drugs Market

  • 26.1. Africa Biologic & Biosimilar RA Drugs Market Overview
  • 26.2. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.3. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Biologic & Biosimilar RA Drugs Market Competitive Landscape And Company Profiles

  • 27.1. Biologic & Biosimilar RA Drugs Market Competitive Landscape
  • 27.2. Biologic & Biosimilar RA Drugs Market Company Profiles
    • 27.2.1. Samsung BioLogics Co. Ltd.
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Amgen Inc.
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Novo Nordisk A/S
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. AbbVie Inc.
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Sanofi Pasteur
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Biologic & Biosimilar RA Drugs Market

29. Biologic & Biosimilar RA Drugs Market Future Outlook and Potential Analysis

30. Appendix

  • 30.1. Abbreviations
  • 30.2. Currencies
  • 30.3. Historic And Forecast Inflation Rates
  • 30.4. Research Inquiries
  • 30.5. The Business Research Company
  • 30.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!